ImmunoCellular plummets on ICT-107 Phase II miss

ImmunoCellular Therapeutics tried to put a positive spin on statistically significant progression-free survival (PFS) for newly-diagnosed glioblastoma multiforme patients treated with the dendritic cell-based cancer vaccine ICT-107 in a Phase II clinical trial, but the company's stock dropped by more than half based on the trial's missed overall survival (OS) primary endpoint.

ImmunoCellular Therapeutics tried to put a positive spin on statistically significant progression-free survival (PFS) for newly-diagnosed glioblastoma multiforme patients treated with the dendritic cell-based cancer vaccine ICT-107 in a Phase II clinical trial, but the company's stock dropped by more than half based on the trial's missed overall survival (OS) primary endpoint.

Los Angeles-based ImmunoCellular's already small market cap shrank from $155.3m to about $71.9m in after-hours trading on 11 December as...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Anticancer

More from Therapeutic Category